Clinical trials
Lymphoma trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Active, not recruiting | 9 |
| Terminated | 4 |
| Recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 4 |
| Bristol-Myers Squibb | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Seagen Inc. | 3 |
| ADC Therapeutics S.A. | 2 |
| Brno University Hospital | 2 |
| Celgene | 2 |
| Genmab | 2 |
| Loxo Oncology, Inc. | 2 |
| Takeda | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma | 43 |
| Lymphoma, Non-Hodgkin | 20 |
| Lymphoma, Large B-Cell, Diffuse | 14 |
| Recurrence | 10 |
| Lymphoma, Follicular | 9 |
| Hematologic Diseases | 8 |
| Neoplasms | 7 |
| Hodgkin Disease | 6 |
| Lymphoma, B-Cell | 6 |
| Lymphoma, Mantle-Cell | 6 |
Trials
Showing 51 to 43 of 43. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.